Seema A. Bhat

Reata Pharmaceuticals (United States) — United States

Medicine · Health Sciences

23h-index2.6kcitations160works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(132), Lymphoma Diagnosis and Treatment(68), Chronic Myeloid Leukemia Treatments(30), Immunodeficiency and Autoimmune Disorders(26), Acute Lymphoblastic Leukemia research(14)

Publications160 total

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B‐Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
European Journal Of Haematology·2025Open Access
A Single, Interpretable Vocal Biomarker for Enriching Antipsychotic Clinical Trials
Biological Psychiatry·2025· 1 cited
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Blood Cancer Discovery·2025· 1 cited
Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease
Blood·2025Open Access
MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
Blood·2025Open Access
A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation
Blood·2025Open Access
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia
Blood·2025Open Access
Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).
Blood·2025Open Access
Considerations for the practical management of cardiovascular risk with Bruton’s tyrosine kinase inhibitors for patients with chronic lymphocytic leukemia
The Oncologist·2025· 6 citedOpen Access
Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton’s Tyrosine Kinase Inhibitors
Hematology/Oncology Clinics of North America·2025· 1 cited
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
American Journal of Hematology·2025· 1 citedOpen Access
A hybrid trial approach by combining 13C8-lableded and radiolabeled brilaroxazine to assess absolute bioavailability and hame in a single clinical trial
Drug Metabolism and Pharmacokinetics·2025
194 | A NOVEL APPROACH FOR CLASSIFICATION OF SPLENIC B CELL LYMPHOMA USING DNA METHYLATION REVEALS DIVERSE BIOLOGICAL DISEASE MECHANISMS
Hematological Oncology·2025Open Access
Unexpected major circulating metabolite M219 detected in 14C-labeled human adme study of brilaroxazine
Drug Metabolism and Pharmacokinetics·2025
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Blood Cancer Journal·2025· 11 citedOpen Access
3: Comparing and contrasting karyotype scoring guidelines for evaluating complex karyotype in chronic lymphocytic leukemia
Genetics in Medicine Open·2025Open Access
Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia
Blood·2024· 7 citedOpen Access
26. Ethanol and HBV: unraveling the pathogenic interactions
Alcohol·2024
TP53 Gain-of-Function Mutants Display Unique Transcriptional Profiles in Chronic Lymphocytic Leukemia
Blood·2024Open Access
A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL
Blood·2024
page 1 of 8Next →

Frequent Co-authors

Kerry A. Rogers(36), Jennifer A. Woyach(34), John C. Byrd(26), Adam S. Kittai(19), Michael R. Grever(16), Ying Huang(14), Gerard Lozanski(11), Tracy Wiczer(10), Farrukh T. Awan(9), James S. Blachly(9), John C. Byrd(8), Deborah M. Stephens(8), David A. Bond(8), Samantha Jaglowski(7), Daniel Addison(6), Amy S. Ruppert(6), Cecelia Miller(6), Patrick Ruz(5), Qiuhong Zhao(5), Kami J. Maddocks(4)